维昇药业-B(02561)

34.100+0.720+2.16%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
维昇药业-B
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.visenpharma.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
维昇药业是一家主要从事开发并商业化颠覆式内分泌疗法的投资控股公司。该公司的主要在研产品包括隆培促生长素、那韦培肽和帕罗培特立帕肽。隆培促生長素用于治疗3至17岁儿童生长激素缺乏症患者。那韦培肽是一款用于治疗2至10岁软骨发育不全儿童患者的疾病修复疗法。帕罗培特立帕肽是一款用于治疗成人甲状旁腺功能减退症的治疗方法。该公司处于研发后期、产品接近商业化。
- 2025-09-19
  半年度报告
  2025中期报告
  2025中期报告
- 2025-08-27
  半年度报告
  (1)截至2025年6月30日止六个月中期业绩公告；(2)非执行董事辞任及委任独立非执行董事；及(3)审计委员会组成变动
  (1)截至2025年6月30日止六个月中期业绩公告；(2)非执行董事辞任及委任独立非执行董事；及(3)审计委员会组成变动
- 2025-04-30
  股份购回
  (1)建议重选退任董事；(2)建议授出购回及发行股份以及出售或转让库存股份之一般授权；(3)建议重新委任核数师；及(4)股东周年大会通告
  (1)建议重选退任董事；(2)建议授出购回及发行股份以及出售或转让库存股份之一般授权；(3)建议重新委任核数师；及(4)股东周年大会通告
- 2025-04-30
  年度报告
  2024 年度报告
  2024 年度报告
- 2025-03-27
  年度报告
  截至2024年12月31日止年度财务业绩
  截至2024年12月31日止年度财务业绩
- 2025-03-13
  股份发售
  全球发售
  全球发售

分时
5日
日
周
月

数据加载中...

最高

34.160

今开

33.000

量比

0.38

最低

33.000

昨收

33.380

换手率

0.00%

热议股票

{"pagemeta":{"title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维昇药业-B,02561,维昇药业-B股票,维昇药业-B股票老虎,维昇药业-B股票老虎国际,维昇药业-B行情,维昇药业-B股票行情,维昇药业-B股价,维昇药业-B股市,维昇药业-B股票价格,维昇药业-B股票交易,维昇药业-B股票购买,维昇药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"fillings","symbol":"02561","data":{"stockData":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维昇药业-B","latestPrice":34.1,"timestamp":1771214886005,"preClose":33.38,"halted":0,"volume":2000,"delay":0,"changeRate":0.021569802276812426,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"农历年初三休市","change":0.72,"latestTime":"02-16 12:08:06","open":33,"high":34.16,"low":33,"amount":66304,"amplitude":0.034751,"askPrice":34.06,"askSize":600,"bidPrice":33.02,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.087,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771551000000},"marketStatusCode":7,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":33.38,"openAndCloseTimeList":[[1771205400000,1771214400000]],"volumeRatio":0.37542661603513156,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":null,"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"20188226","market":"hk","labels":[],"media":"港交所","original_id":"N.HKGJnTAK4iYq","pdf_url":"https://static.tigerbbs.com/49097213e22f489f964f6e056420bb34","pub_time":1758293820000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025中期报告","symbol":"02561","title":"2025中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0919/2025091901919_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-09-19 22:57","pubTimestamp":1758293820,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20078163","market":"hk","labels":[],"media":"港交所","original_id":"N.HK57P4dpvD74","pdf_url":"https://static.tigerbbs.com/eaa3627a782e4a04993dcbccefc526cd","pub_time":1756305240000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"(1)截至2025年6月30日止六个月中期业绩公告；(2)非执行董事辞任及委任独立非执行董事；及(3)审计委员会组成变动","symbol":"02561","title":"(1)截至2025年6月30日止六个月中期业绩公告；(2)非执行董事辞任及委任独立非执行董事；及(3)审计委员会组成变动","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0827/2025082702204_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-08-27 22:34","pubTimestamp":1756305240,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19583170","market":"hk","labels":[],"media":"港交所","original_id":"N.HKA3hSuFEznG","pdf_url":"https://static.tigerbbs.com/fc64608f35df45f3980cc552a65502bd","pub_time":1746003300000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"(1)建议重选退任董事；(2)建议授出购回及发行股份以及出售或转让库存股份之一般授权；(3)建议重新委任核数师；及(4)股东周年大会通告","symbol":"02561","title":"(1)建议重选退任董事；(2)建议授出购回及发行股份以及出售或转让库存股份之一般授权；(3)建议重新委任核数师；及(4)股东周年大会通告","titleType":"股份购回","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0430/2025043001617_c.pdf","us_notice_code":"通函 - [一般性授权 / 回购股份的说明函件 / 在股东批准的情况下重选或委任董事]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Repurchase","event_type":"important_notice","event_name":"股份购回","pubTime":"2025-04-30 16:55","pubTimestamp":1746003300,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19583036","market":"hk","labels":[],"media":"港交所","original_id":"N.HK9GkPgF5Biu","pdf_url":"https://static.tigerbbs.com/cd8a5a39262f4dc1b0aa707212339bcd","pub_time":1746002880000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024 年度报告","symbol":"02561","title":"2024 年度报告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0430/2025043001436_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报 / 环境、社会及管治资料/报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-04-30 16:48","pubTimestamp":1746002880,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19295629","market":"hk","labels":[],"media":"港交所","original_id":"N.HKGCGp8NQist","pdf_url":"https://static.tigerbbs.com/e077615e0f0f40ac9e539197ee98b8f8","pub_time":1743076980000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年12月31日止年度财务业绩","symbol":"02561","title":"截至2024年12月31日止年度财务业绩","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0327/2025032701648_c.pdf","us_notice_code":"公告及通告 - [末期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-03-27 20:03","pubTimestamp":1743076980,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19232777","market":"hk","labels":[],"media":"港交所","original_id":"N.HK4bwi4bC9ha","pdf_url":"https://static.tigerbbs.com/061a491568ea4cb3bc3199701afb1b9c","pub_time":1741817640000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"全球发售","symbol":"02561","title":"全球发售","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0313/2025031300018_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2025-03-13 06:14","pubTimestamp":1741817640,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"websiteUrl":"http://www.visenpharma.com","stockEarnings":[{"period":"1week","weight":0.024},{"period":"1month","weight":0.0089},{"period":"3month","weight":-0.0023},{"period":"6month","weight":-0.2616},{"period":"1year","weight":-0.5044},{"period":"ytd","weight":0.0396}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0052},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.0612},{"period":"1year","weight":0.1806},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"维昇药业是一家主要从事开发并商业化颠覆式内分泌疗法的投资控股公司。该公司的主要在研产品包括隆培促生长素、那韦培肽和帕罗培特立帕肽。隆培促生長素用于治疗3至17岁儿童生长激素缺乏症患者。那韦培肽是一款用于治疗2至10岁软骨发育不全儿童患者的疾病修复疗法。帕罗培特立帕肽是一款用于治疗成人甲状旁腺功能减退症的治疗方法。该公司处于研发后期、产品接近商业化。","exchange":"SEHK","name":"维昇药业-B","nameEN":"VISEN PHARMA-B"},"aProfile":null}}}